Ocugen
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 65
- Market Cap
- $382.8M
- Website
- http://www.ocugen.com
- Introduction
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Expanded Access Program for RP in Adults
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Ocugen
- Registration Number
- NCT06574997
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Advanced Research, Deerfield Beach, Florida, United States
🇺🇸Erie Retina Research, Erie, Pennsylvania, United States
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- Genetic: Sub-Retinal Administration of OCU400-301
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 150
- Registration Number
- NCT06388200
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸University of Southern Califormia, La Jolla, California, United States
🇺🇸University of Southern California, Roski Eye Insitute, Los Angeles, California, United States
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
- Conditions
- Geographic Atrophy
- Interventions
- Genetic: OCU410
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 60
- Registration Number
- NCT06018558
- Locations
- 🇺🇸
Advanced Research, LLC, Coral Springs, Florida, United States
🇺🇸The Retina Institute, Saint Louis, Missouri, United States
🇺🇸Valley retina Institute, McAllen, Texas, United States
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
- Conditions
- Stargardt Disease
- Interventions
- Genetic: OCU410ST
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 42
- Registration Number
- NCT05956626
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Mississippi Retina Associates, Jackson, Mississippi, United States
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
- Conditions
- Center Involved Diabetic Macular EdemaDiabetic Macular Edema
- Interventions
- Drug: OCU200 Low DoseDrug: OCU200 Medium DoseDrug: OCU200 High Dose
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 28
- Registration Number
- NCT05802329
- Locations
- 🇺🇸
Advanced Research LLC, Deerfield Beach, Florida, United States
🇺🇸Erie Retina Research, LLC, Erie, Pennsylvania, United States
🇺🇸Retina Consultants of Texas Research Centers, Bellaire, Texas, United States
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
- Conditions
- COVID-19
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Ocugen
- Registration Number
- NCT05541289
- Locations
- 🇺🇸
Woods, Langhorne, Pennsylvania, United States
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
- Conditions
- COVID-19
- Interventions
- Biological: BBV152
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 400
- Registration Number
- NCT05258669
- Locations
- 🇺🇸
Voyage Medical, Tempe, Arizona, United States
🇺🇸Palm Springs Community Health Center, Miami Lakes, Florida, United States
🇺🇸Angels Clinical Institute, Miami, Florida, United States
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
- Conditions
- Retinitis PigmentosaLeber Congenital Amaurosis
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 124
- Registration Number
- NCT05203939
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Ocugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute, La Jolla, California, United States
🇺🇸Ocugen Site 3 - Bascom Palmer Eye Institute, Miami, Florida, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 252
- Registration Number
- NCT03785340
- Locations
- 🇺🇸
Aesthetic Eye Care Institute/David Wirta, MD and Associates, Newport Beach, California, United States
🇺🇸Martel Medical Eye Group, Rancho Cordova, California, United States
🇺🇸Rand Eye Institute, Pompano Beach, Florida, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
- Conditions
- oGVHDOcular Graft vs Host DiseaseLubricant Eye DropsGraft Versus Host DiseaseOphthalmic SolutionsOcular Surface DiseaseBrimonidine TartrateGraft vs Host Disease
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 59
- Registration Number
- NCT03591874
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸Emory Eye Center, Atlanta, Georgia, United States